TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed on January 2, 2024. The company had previously been notified by Nasdaq on June 22, 2023, that it did not meet the minimum bid price of $1.00 for 30 consecutive business days. To address this, TC BioPharm was required to maintain a closing bid price of at least $1.00 for 10 consecutive business days. This condition was fulfilled on December 29, 2023, leading to the company's compliance with Nasdaq Listing Rule 5550(a)(2). The company issued a press release on January 4, 2024, to announce the regained compliance. TC BioPharm focuses on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting clinical trials for its product line, including a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia.

TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has successfully regained compliance with the Nasdaq minimum bid price requirement, as confirmed on January 2, 2024. The company had previously been notified by Nasdaq on June 22, 2023, that it did not meet the minimum bid price of $1.00 for 30 consecutive business days. To address this, TC BioPharm was required to maintain a closing bid price of at least $1.00 for 10 consecutive business days. This condition was fulfilled on December 29, 2023, leading to the company's compliance with Nasdaq Listing Rule 5550(a)(2). The company issued a press release on January 4, 2024, to announce the regained compliance. TC BioPharm focuses on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting clinical trials for its product line, including a Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia.